Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Parbendazole is a benzimidazole anthelmintic primarily utilized in veterinary medicine for the control of gastrointestinal nematodes in livestock such as sheep, cattle, and swine. Its primary mechanism of action involves high-affinity binding to the colchicine-sensitive site of beta-tubulin, which inhibits microtubule polymerization and disrupts essential cellular functions, including glucose uptake and waste excretion in parasites. Beyond its veterinary applications, parbendazole is frequently employed as a research tool in cell biology to study cytoskeletal dynamics and phenotypic profiling. It has been explored in preclinical studies for potential repositioning as an anti-cancer agent due to its ability to induce mitotic arrest and apoptosis in mammalian cells by interfering with microtubule assembly.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on parbendazole.